CAPRIN1 Antibody

What is CAPRIN1 and why is it important in scientific research?

CAPRIN1 (Cytoplasmic Activation/Proliferation-Associated Protein 1) functions primarily as an mRNA-binding protein that regulates mRNA transport, translation, and stability. It plays essential roles in neurogenesis, synaptic plasticity, and cell proliferation across multiple cell types . The protein is particularly significant in research due to its involvement in:

• Cytoplasmic stress granule formation through phosphorylation mechanisms

• Liquid-liquid phase separation upon binding to target mRNAs

• Formation of ribonucleoprotein granules that concentrate mRNAs with regulatory factors

• Direct binding to specific mRNAs including MYC, CCND2, BDNF, and CAMK2A

• Viral replication complex control in RNA virus infections

Importantly, CAPRIN1 has recently gained attention because it demonstrates strong membrane expression in numerous cancer types while remaining absent from normal tissue cell membranes, making it a promising cancer-specific target for therapeutic approaches .

What are the standard applications for CAPRIN1 antibodies in cellular research?

CAPRIN1 antibodies serve multiple research applications with specific methodological parameters:

When implementing these techniques, researchers should note that CAPRIN1 demonstrates different subcellular localization patterns depending on cellular conditions. Under normal conditions, it predominantly shows cytoplasmic localization, while under stress conditions, it relocates to stress granules. In cancer cells, a significant portion may be expressed on the cell membrane .

How can researchers validate the specificity of CAPRIN1 antibodies?

Methodological validation of CAPRIN1 antibodies should include:

• RNAi knockdown experiments: Compare antibody signal in wild-type cells versus CAPRIN1 knockdown cells. A significant reduction in signal confirms specificity .

• Reconstitution studies: As demonstrated in viral replication research, CAPRIN1 knockdown followed by reconstitution with CAPRIN1 expression can verify both antibody specificity and rule out off-target effects .

• Immunoprecipitation followed by mass spectrometry: This identifies CAPRIN1-interacting proteins and confirms antibody specificity through the detection of known CAPRIN1 binding partners such as G3BP1 .

• Multiple antibody comparison: Using different antibodies targeting distinct epitopes of CAPRIN1 helps validate detection patterns. For example, antibodies recognizing the region within amino acids 550-600 have shown consistent results .

• Cross-reactivity testing: Evaluate potential cross-reactivity with structurally related proteins, particularly other RNA-binding proteins that may share similar domains.

What methodological approaches are recommended for detecting membrane-bound versus cytoplasmic CAPRIN1?

Distinguishing between membrane-bound and cytoplasmic CAPRIN1 requires specific methodological considerations:

For membrane CAPRIN1 detection:

• Cell surface biotinylation: Label surface proteins with biotin reagents that do not penetrate the membrane, followed by streptavidin pulldown and Western blotting with anti-CAPRIN1 antibodies.

• Flow cytometry: Perform on non-permeabilized cells to detect only membrane-expressed CAPRIN1. This approach was crucial in identifying CAPRIN1 as a cancer-specific membrane target .

• Immunofluorescence confocal microscopy: Use membrane markers (e.g., WGA) alongside CAPRIN1 antibodies to assess colocalization at the membrane.

For cytoplasmic CAPRIN1 analysis:

• Subcellular fractionation: Separate cytosolic, nuclear, and membrane fractions before Western blotting.

• Immunofluorescence on permeabilized cells: Use detergents like Triton X-100 to permeabilize cells before staining with CAPRIN1 antibodies.

Research has shown that while normal cells express CAPRIN1 primarily in the cytoplasm, cancer cells uniquely express CAPRIN1 on the cell membrane. This differential expression pattern provides both diagnostic and therapeutic opportunities in cancer research .

What controls should researchers implement when working with CAPRIN1 antibodies?

Methodologically rigorous experiments with CAPRIN1 antibodies require the following controls:

When studying membrane CAPRIN1 expression specifically, comparing cancer versus normal tissue samples is critical, as studies have demonstrated that CAPRIN1 membrane expression is highly specific to cancer cells including cancer stem cells and EMT-induced metastatic cancer cells .

How do researchers optimize CAPRIN1 antibody concentrations for different applications?

Optimization strategies for CAPRIN1 antibodies across applications include:

For Western Blot:

• Test a concentration gradient (0.04-0.4 μg/mL is typically effective)

• Optimize blocking conditions (5% BSA is often preferred for phospho-specific detection)

• Adjust incubation time and temperature (overnight at 4°C may improve signal-to-noise ratio)

For Immunofluorescence:

• Begin with 0.25-2 μg/mL concentration range

• Test different fixation methods (paraformaldehyde vs. methanol)

• Evaluate permeabilization conditions depending on target localization

• Include antigen retrieval steps if necessary

For Immunohistochemistry:

• Start with 1:500-1:1000 dilution as recommended

• Optimize antigen retrieval methods (heat-induced vs. enzymatic)

• Test visualization systems (DAB vs. fluorescent secondary antibodies)

Titration experiments should be performed for each new cell line or tissue type, as CAPRIN1 expression levels vary significantly across different cancer types and experimental conditions.

How can researchers investigate CAPRIN1's role in stress granule formation?

Methodological approaches to study CAPRIN1's function in stress granule formation include:

• Stress induction protocols: Treat cells with sodium arsenite, thapsigargin, or heat shock to induce stress granule formation, then analyze CAPRIN1 localization.

• Co-immunoprecipitation of stress granule components: Use CAPRIN1 antibodies to pull down associated proteins, followed by mass spectrometry to identify stress granule components.

• Live-cell imaging: Express fluorescently tagged CAPRIN1 to track its dynamic recruitment to stress granules in real-time.

• Proximity labeling techniques: Employ BioID or APEX2 fused to CAPRIN1 to identify proximal proteins in stress granules.

• Phase separation analysis: Investigate CAPRIN1's liquid-liquid phase separation properties through in vitro reconstitution assays with purified components.

Research has shown that CAPRIN1 undergoes liquid-liquid phase separation following phosphorylation and interaction with FMR1, which promotes the formation of cytoplasmic ribonucleoprotein granules. Within these structures, CAPRIN1 mediates recruitment of the CNOT7 deadenylase, leading to mRNA deadenylation and degradation .

What techniques are recommended for studying CAPRIN1's involvement in viral replication complex inhibition?

Investigating CAPRIN1's role in viral replication requires specialized approaches:

• Infection models: Utilize murine norovirus (MNV) as a model system, as studies have demonstrated CAPRIN1's involvement in controlling MNV replication complexes .

• Knockdown and reconstitution experiments: Implement shRNA-mediated CAPRIN1 knockdown followed by reconstitution to assess functional effects on viral replication. This approach revealed that CAPRIN1 knockdown reduced interferon-gamma inhibition of MNV by approximately 1,000-fold .

• Colocalization studies: Employ immunofluorescence microscopy to visualize CAPRIN1 colocalization with viral replication complexes and autophagy proteins like ATG16L1 and LC3 .

• Protein interaction analysis: Use co-immunoprecipitation to confirm interactions between CAPRIN1, viral components, and autophagy machinery proteins. Research has confirmed that ATG16L1 interacts with CAPRIN1 via co-IP .

• Viral replication assays: Quantify viral replication through plaque assays or qRT-PCR in the presence or absence of CAPRIN1.

CAPRIN1 appears to be required for LC3 localization with viral replication complexes and for interferon-gamma-mediated control of viral replication, suggesting its crucial role in the autophagy machinery-mediated recognition and inhibition of viral replication complexes .

How can researchers utilize CAPRIN1 antibodies to study its role in cancer progression?

CAPRIN1's emerging role in cancer provides multiple research avenues:

• Membrane expression profiling: Use flow cytometry and immunohistochemistry with CAPRIN1 antibodies to evaluate membrane expression across cancer types. Research has shown that CAPRIN1 is strongly expressed on the cell membrane in most solid cancers but not normal tissues .

• Cancer stem cell identification: Employ CAPRIN1 antibodies to identify and isolate cancer stem cell populations, as CAPRIN1 membrane expression extends to highly tumorigenic cancer stem cells .

• EMT analysis: Utilize CAPRIN1 antibodies to study its expression in epithelial-mesenchymal transition (EMT)-induced metastatic cancer cells .

• Tumorigenicity assessment: Isolate cancer cells with high CAPRIN1 surface expression to evaluate their enhanced tumorigenicity in colony formation assays and xenograft models .

• Therapeutic antibody development approach: Review the methods used to generate the therapeutic anti-CAPRIN1 antibody TRK-950, which involved:

  • Immunization with recombinant human CAPRIN1 protein

  • Screening hybridoma supernatants for binding to CAPRIN1 protein by ELISA

  • Assessing binding to cancer cell membrane surface by flow cytometry

  • Purification using rProtein A Sepharose Fast Flow

This research has led to the development of TRK-950, which has shown promising results in clinical trials, particularly in gastric/gastroesophageal junction cancer when combined with ramucirumab and paclitaxel .

What methodologies are effective for investigating CAPRIN1's mRNA regulatory functions?

To study CAPRIN1's role in mRNA regulation:

• RNA immunoprecipitation (RIP): Use CAPRIN1 antibodies to isolate CAPRIN1-bound mRNAs, followed by sequencing or qRT-PCR to identify target transcripts. Studies have identified direct binding to MYC and CCND2 mRNAs .

• Crosslinking and immunoprecipitation (CLIP): Apply UV crosslinking before immunoprecipitation to capture direct RNA-protein interactions with higher specificity.

• Ribosome profiling: Compare translational efficiency of CAPRIN1 target mRNAs in wild-type versus CAPRIN1-depleted cells.

• mRNA stability assays: Measure half-lives of candidate target mRNAs after transcriptional inhibition in CAPRIN1-manipulated cells.

• In vitro reconstitution of phase separation: Combine purified CAPRIN1 with target mRNAs to observe liquid-liquid phase separation and formation of ribonucleoprotein granules.

Research indicates that CAPRIN1 selectively binds to specific mRNAs involved in neuronal function (BDNF, CAMK2A, CREB1), as well as cell proliferation and growth (MYC, CCND2). Through phase separation, CAPRIN1 assembles these mRNAs into cytoplasmic ribonucleoprotein granules that concentrate mRNAs with associated regulatory factors .

How can researchers interpret CAPRIN1 expression patterns in clinical samples?

When analyzing CAPRIN1 expression in clinical samples:

• Membrane versus cytoplasmic staining: Carefully distinguish between membrane and cytoplasmic localization, as membrane expression is highly cancer-specific and associated with enhanced tumorigenicity .

• Expression in cancer stem cells: Implement double staining for CAPRIN1 and cancer stem cell markers to identify highly tumorigenic populations .

• Correlation with clinical parameters: Analyze CAPRIN1 expression in relation to:

  • Tumor stage and grade

  • Metastatic potential

  • Patient survival

  • Treatment response

• Quantification methods: Employ digital pathology and image analysis software to quantitatively assess membrane versus cytoplasmic CAPRIN1 staining intensity.

The differential expression pattern of CAPRIN1—membrane localization in cancer cells versus cytoplasmic localization in normal cells—makes it a valuable biomarker for cancer diagnosis and a promising therapeutic target. Multiple reports have demonstrated that intracellular expression of CAPRIN1 positively correlates with cancer progression and poor prognosis .

What can researchers learn from clinical trials of therapeutic anti-CAPRIN1 antibodies?

The development of therapeutic anti-CAPRIN1 antibodies provides insights for researchers:

Particularly notable are the results from Regimen D in the Phase 1b trial, which evaluated TRK-950 in combination with ramucirumab and paclitaxel in gastric/gastroesophageal junction cancer. This regimen showed a disease control rate of 100% in all nine patients receiving 10 mg/kg, with partial responses observed in 5/9 (55%) patients. Strong CAPRIN1 expression was observed in 4/9 patients, and those patients showed a 100% objective response rate .

These findings suggest that CAPRIN1 expression levels may serve as a predictive biomarker for response to anti-CAPRIN1 therapy, highlighting the importance of accurate CAPRIN1 detection and quantification methods in clinical research.

How should researchers address discrepancies in CAPRIN1 antibody staining patterns?

When encountering inconsistent CAPRIN1 staining results:

• Epitope accessibility: Different fixation methods may affect epitope exposure. If discrepancies occur, test multiple fixation protocols (4% paraformaldehyde, methanol, acetone).

• Antibody validation: Confirm antibody specificity through RNAi knockdown experiments. Significant signal reduction in knockdown cells confirms specificity .

• Cell state considerations: CAPRIN1 localization changes under stress conditions. Standardize cell culture conditions and stress exposure times.

• Membrane preparation techniques: For membrane CAPRIN1 detection, gentle cell lysis and membrane fraction isolation are critical to preserve membrane integrity.

• Cross-antibody validation: Use multiple antibodies targeting different CAPRIN1 epitopes to confirm staining patterns.

Methodological discrepancies may also arise from different phosphorylation states of CAPRIN1, as phosphorylation affects its phase separation properties and interactions with other proteins .

What are the key considerations when analyzing CAPRIN1's role in complex with other proteins?

When investigating CAPRIN1 protein interactions:

• Preserving physiological complexes: Use mild lysis conditions to maintain native protein interactions during immunoprecipitation.

• Confirming direct interactions: Implement proximity ligation assays or FRET to verify direct protein-protein interactions in situ.

• Mapping interaction domains: Generate truncation or point mutants to identify specific domains required for protein interactions.

• Context-dependent interactions: Assess how cellular conditions (stress, viral infection) affect CAPRIN1's interaction partners.

• Liquid-liquid phase separation consideration: Evaluate how phase separation affects protein complex formation and function.

Research has shown important interactions between CAPRIN1 and several key proteins:

• ATG16L1: CAPRIN1 interacts with ATG16L1 and colocalizes with viral replication complexes during infection

• G3BP1: CAPRIN1 interacts with viral replication complexes via G3BP1

• FMR1: CAPRIN1 undergoes liquid-liquid phase separation following phosphorylation and interaction with FMR1

• CNOT7: CAPRIN1 mediates recruitment of CNOT7 deadenylase to ribonucleoprotein granules

Understanding these interactions is crucial for elucidating CAPRIN1's diverse roles in cellular processes and disease states.